Role of CDK8 and β-catenin in colorectal adenocarcinoma

JONG-OG SEO¹, SONG IY HAN² and SUNG-CHUL LIM¹,²

¹Department of Pathology and ²Research Center for Resistant Cells, Chosun University School of Medicine, 588, Seosuk-dong, Dong-gu, Gwangju, Republic of Korea

Received March 5, 2010; Accepted April 29, 2010

DOI: 10.3892/or_00000858

Abstract. Colorectal adenocarcinoma is a major cause of morbidity and mortality. The Wnt/β-catenin pathway plays an important role in colon cancers. However, relatively little is known about the regulatory mechanism of β-catenin in colon cancers. CDK8 is a cyclin-dependent kinase (CDK) member of the mediator complex that couples transcriptional regulators to the basal transcriptional machinery, and is implicated in the transcriptional regulation of key pathways involved in colon cancers. To determine the relationship between CDK8 and β-catenin expressions, a population-based study was conducted for immunohistochemical staining analysis of tumor tissues, and Western blot analysis and CDK8 interference studies of colon cancer cell lines. The hypothesis that colorectal cancers with CDK8 expression have distinct clinical, prognostic and molecular attributes was tested. Among 127 colorectal cancers, CDK8 expression was detected in 96 (76%) tumors by immunohistochemistry. CDK8 and β-catenin expression had significant positive correlation with carcinogenesis, tumor progression and patient survival. Immunohistochemically, CDK8 expression in colorectal cancer was independently associated with β-catenin activation (P=0.0002). However, β-catenin expression was not completely suppressed by CDK8 interference in the colon cancer cell lines HCT-116, HT-29 and SNU-C5. These data support a potential link between CDK8 and β-catenin, and suggest that CDK8 may identify a subset of colon cancer patients with a poor prognosis. However, control of CDK8 is not an effective therapeutic strategy through β-catenin regulation of general colon cancer.

Introduction

The Wnt/β-catenin pathway involved in the early development process of various cancers is also involved in the development of colorectal cancer (1,2). β-catenin is the central nuclear effector in the Wnt signal transduction system. Under physiological conditions, Wnt contributes to the stabilization of β-catenin, and once stabilized, β-catenin is accumulated, and translocates to the nucleus. The impairment of the regulation of the Wnt/β-catenin pathway (particularly, mutation in APC) plays an important role in the initiation of colorectal cancer (3). Studies on the mechanism of the stabilization of β-catenin within the cytoplasm and the translocation to the nucleus has been conducted, nonetheless, the understanding of the mechanism of the accumulation of nonphosphorylated β-catenin in the nucleus activating the transcription of the target genes cyclin D1, c-myc, c-jun is still insufficient (4).

CDK8 is located in chromosome 13, forms a pair with transcriptional regulators, and is involved in the regulation of the transcription involved in the formation of colorectal cancer (5). In addition, for β-catenin-dependent transcription and oncogenesis, activation of CDK8 kinase is essential (6,7). Therefore, it was determined that studies on CDK8 and β-catenin using human colorectal tissues would provide an important direction for chemotherapy using β-catenin regulators in the future. Therefore, we evaluated the immunohistochemical expression level or pattern of CDK8 and β-catenin according to several clinicopathological factors using colorectal cancer tissues, and analyzed the mutual correlation of CDK8 and β-catenin. To confirm the validity of the result of immunohistochemical study performed on the colorectal cancer tissues, molecular pathological studies using colorectal cancer cell lines were performed.

Materials and methods

Case selection and tissue sampling. Among patients who underwent curative surgery for colorectal adenocarcinoma at our hospital from January 1992 to December 2004, non-consecutive 127 patients were selected with relatively well preserved paraffin-embedded tissues, complete medical records, and a known follow-up status. The various clinicopathological parameters of the patients were confirmed by a review of the patient charts and pathology files. Patient survival was confirmed through telephone calls and by mail. Ten cases of colon adenoma and 10 cases of normal-looking colon mucosa, which were all obtained endoscopically, were subjected to immunohistochemical analysis for a comparison study.

Those patients who underwent preoperative chemoradiotherapy and emergency surgery, and those patients that had evidence of hereditary non-polyposis colorectal cancer or
familial adenomatous polyposis were excluded from the study. Informed consent was obtained from each subject according to the institutional guidelines, and the research protocols were approved by the IRB of our hospital.

**Histopathological analysis**

*Microscopic examination.* Each tumor was re-evaluated by Histopathological analysis protocols were approved by the IRB of our hospital. Informed consent was obtained from each subject familial adenomatous polyposis were excluded from the study. Informed consent was obtained from each subject.

The stage was defined according to the TNM staging system of the American Joint Committee on Cancer (8). Tissues to be examined were fixed in 10% neutral formalin, and the prepared paraffin-embedded tissues were sectioned 4-5 μm in thickness, and hematoxylin and eosin staining was performed. The cells were examined under a light microscope, the representative area suitable to the study purpose was selected, and slides were prepared for immunohistochemical analysis.

**Immunohistochemical staining.** Briefly, the 4-μm sections that were obtained after formalin fixation and paraffin embedding were deparaffinized in xylene and were rehydrated with distilled water through a graded series of ethanol solutions. The sections were then placed in a glass jar with 10 mM citrate buffer (pH 6.0) and irradiated in a microwave oven for 15 min, and were allowed to cool down in the jar at room temperature for 20 min. The slides were then rinsed with Tris buffered saline (TBS). Blocking reagent was added for 10 min after quenching the endogenous peroxidase activity in 0.3% hydrogen peroxide for 10 min. The slides were then washed as before, and they were subsequently subjected to the primary antibody reaction. Mouse monoclonal β-catenin (Santa Cruz Biotechnology, Santa Cruz, CA, USA, dilution 1:200) and rabbit polyclonal CDK8 (Santa Cruz Biotechnology, dilution 1:200) applied to the tissue section and they were allowed to incubate in a moist chamber for 1 h at room temperature. After washing with TBS, Polink-2 HRP plus mouse DAB detection system (Golden Bridge International, Inc., WA, USA) and Polink-2 HRP plus rabbit DAB detection mouse anti-actin was purchased from Sigma (St. Louis, MO, USA). Unless specified, drugs were purchased from Gibco BRL.

**Western blot analysis of CDK8 and β-catenin**

*Cell culture.* Human-derived colon cancer cell lines HCT116 (11), HT29 (12) and SNU-C5 (13) were seeded with 1.5x10⁶ cells in a 10-cm petri dish and maintained in RPMI-1640 medium (Invitrogen) containing 10% FBS (Gibco BRL, Grand Island, NY, USA) and 1X antibiotic-antimycotic (Gibco BRL) at 37°C in 5% CO₂. After overnight incubation, the indicated drugs were treated at various time points. These cell lines were established from colon adenocarcinoma which had no history of anti-cancer chemotherapy or radiotherapy.

*Reagents.* Polyclonal rabbit anti-human CDK8 (H-139), monoclonal anti-β-catenin (E-5) and ECL system were purchased from Santa Cruz Biotechnology and monoclonal mouse anti-actin was purchased from Sigma (St. Louis, MO, USA). Unless specified, drugs were purchased from Gibco BRL.

**Analysis and interpretation of staining.** A pathologist who did not know the clinical course of the subjects in order to exclude subjectivity evaluated the staining results. Scoring of β-catenin was based upon the distribution of β-catenin within the cell membrane (0-1), cytoplasm (0-2), and nuclei (0-2), with a total score of 0 reflecting cell membrane staining only, similar to that seen in normal colonic mucosa, up to an aggregate score of 5 for tumors with strong nuclear staining (2), diffuse cytoplasmic staining (2), and loss of cell membrane staining (1). Total scores were then collapsed into two grades (inactive, 0-2; active, 3-5) (9).

CDK8 expression was determined by assessing the level of immunohistochemical staining in tumor cell nuclei. Initially, the overall staining intensity was scored as none, weak, moderate or strong. Cases categorized as positive were those characterized by weak, moderate or strong staining, while cases categorized as negative were those with no nuclear staining (10).

**Results**

*Clinicopathological findings.* The survival to December 31, 2004, of 127 cases examined by immunohistochemical analysis in our study was assessed by telephone and mail. The survival record of the longest survival 156 months (average follow-up period: 58.8±32.7 months) could be confirmed. One hundred and twenty-seven cases showed T...
Clinicopathological significance of CDK8

Immunoreactivity for CDK8. Immunohistochemical staining was performed on 127 cases of colorectal cancer. The disease stage was I-IV. Among them, 96 cases (76%) showed positive expression of CDK8 in the nucleus (Fig. 1). In the cases that performed the test, examining the rate of the positive expression of CDK8 according to gender, 50 patients of 61 female patients (82%), and 46 patients of 66 male patients (70%) were positive, the females showed a higher positive rate, and it was statistically significant (P<0.005).

In the normal colon mucosa stained in parallel for comparative observation, 1 case (10%) showed positive reaction, and it was weakly positive. In addition, in tubular adenoma cases, 6 cases (60%) showed positivity. One case was weak, 4 cases were moderate, and 1 case showed strong positivity (Table I). Such findings were considered to suggest the involvement of CDK8 in the early process of the formation of colorectal cancer.

Interrelation between CDK8 and T stage. The change of CDK8 according to the T stage was analyzed. In the T stage 4 patients were not included in the analysis subjects, and thus its interpretation is limited. Nonetheless, as the T stage became higher, the expression of CDK8 was elevated. The expression of CDK8 was statistically significantly elevated in the T stage III in comparison with stage I (P<0.005).

Interrelation between CDK8 and lymph node metastasis. Among 41 cases with lymph node metastasis, 38 cases (93%) expressed CDK8. Among 86 cases without lymph node metastasis, 58 cases (67%) expressed CDK8. The expression of CDK8 correlated to lymph node metastasis, and it was statistically significant (P<0.005).

Interrelation between CDK8 and distant metastasis. Only 4 cases with distant metastasis were included in the analysis, and thus it was very limited to interpret statistical significance. Nonetheless, among 123 cases without distant metastasis, 92 cases (75%) showed CDK8 positivity. Four
cases with distant metastasis were CDK8 positive, and thus the expression of CDK8 significantly correlated to distant metastasis (P<0.0005).

Interrelation between CDK8 and clinical stage. There were only 4 patients in clinical stage IV, and thus statistical analysis was limited. The rate of the expression of CDK8 showed a tendency to be increased with the advance of clinical stage, and thus the involvement of CDK8 in the progression of colorectal cancer could be speculated. The rate of the positive expression of CDK8 in the clinical stage III and IV was statistically significantly higher in comparison with the clinical stage I (P<0.01 and P<0.0005, respectively).

Mutual relation of immunohistochemical expression of β-catenin and CDK8
Analysis by intranuclear staining of β-catenin. Nuclear staining was observed in 74 colorectal cancer cases (58%). Forty cases (31%) showed weak expression, and 34 cases (27%) showed moderate/strong expression (Fig. 2). In 53 cases (42%) there was no expression of β-catenin, 33 cases (62%) showed positive expression of CDK8. In the cases that showed positive expression of β-catenin within the nucleus, 78-79% cases showed positive expression of CDK8, and thus the positive expression of β-catenin in the nucleus correlated to the positive expression of CDK8, and it was statistically significant (P<0.05).

Analysis by intracytoplasmic staining of β-catenin. Staining in the cytoplasm was observed in 54 cases of colorectal cancer (43%). Forty-four cases (35%) showed weak expression, and 10 cases (8%) showed moderate/strong expression (Fig. 2). Among 73 cases (57%) without the expression of β-catenin within the cytoplasm, 46 cases (63%) showed positive expression of CDK8. In the cases that showed positive expression of β-catenin in the cytoplasm, in regard to the staining intensity, the positive expression of CDK8 was shown in 75%. In cases showing moderate/strong expression, 80% showed positive expression of CDK8, and thus the expression of β-catenin within the cytoplasm correlated to the positive expression of CDK8, and it was statistically significant (P<0.01 and P<0.005, respectively).

Analysis by cytoplasmic membrane staining of β-catenin. The staining of β-catenin of cell membrane was lost in 76 cases (60%) of colorectal cancer (Fig. 3), and the staining of cell
significant (P<0.05).

Colon cancer cell line study

Western blot analysis - expression of CDK8. Colon cancer cell lines were cultured, and CDK8 was measured. It was strongly expressed in HCT-116, HT-29 and SNU-C5 cell lines (Fig. 4). This suggests the involvement of CDK8 in colorectal cancer as shown in the results of immunohistochemical staining.

Expression of β-catenin. Colon cancer cell lines were cultured and the expression of β-catenin was assessed. It was shown to be expressed strongly in HCT-116, HT-29 and SNU-C5 cell lines. However, in HT-29 cases, the expression of β-catenin was slightly weaker than HCT-116 and SNU-C5 (Fig. 4). This suggests that β-catenin could be expressed by the involvement of CDK8 in colorectal cancer as shown in the result of immunohistochemical staining.

Experiments in the absence of serum. To elucidate the relationship of CDK8 and β-catenin, colorectal cancer cell lines were cultured for 24 h in serum-free medium. In the absence of serum factors, the expression of CDK8 was reduced slightly in HCT-116, HT-29 and SNU-C5 cell lines. However, β-catenin showed a tendency to be expressed more strongly in the medium without serum factors (Fig. 4). In other words, under the condition where serum factors were omitted and thus CDK8 was reduced, β-catenin showed a tendency to be increased.

Expression of β-catenin after treatment of CDK8 siRNA. CDK8 interference was generated, and the expression of β-catenin in the colon cancer cell lines, HCT-116, HT-29 and SNU-C5, was assessed. The expression of β-catenin was decreased noticeably in HCT-116 and SNU-C5; nonetheless, it could not be suppressed completely. In addition, in HT-29 cases, reduction of the expression of β-catenin was not observed (Fig. 5).

Survival analysis by CDK8 expression. To analyze the outcome of patients according to the expression of CDK8, the effect of CDK8 on the survival of colorectal cancer patients was analyzed. The overall 5-year survival rate of patients was 73.3%. At the time of examination, among 127 patients (average follow-up period: 4.9 years), 75 patients survived, and 59.1% survival rate was shown. Among the CDK8 negative group (31 patients), 22 patients (71%) survived. In the CDK8 positive group (96 patients), 53 patients (55%) survived (log-rank: P=0.028) (Fig. 6). Hence, it was found that the expression of CDK8 was closely associated with the high mortality of colorectal cancer patients.

Discussion

The WNT gene as well as its product comprise the WNT signal pathway, and the molecule playing a central role in this signaling pathway is β-catenin, and its stability is regulated by the APC complex. When WNT receptor is inactivated, β-catenin is localized in the membrane protein E-cadherin (CDH1), and kinases in the APC complex phosphorylate β-catenin in the cytoplasm resulting in the induction of its rapid degradation. On the other hand, when WNT is activated, kinases in the APC complex are suppressed resulting in β-catenin accumulating in the cytoplasm, translocated to the nucleus, and stimulating the transcription of various target genes (14). In addition, in the WNT pathway, the TGF-β pathway (15) and the COX-2/prostaglandin pathway are involved in cross-talk (16-18).

The activation of WNT/β-catenin signal has been reported to be involved in the development of various human cancers including colorectal cancer; nonetheless, studies on the relationship of CDK8 and β-catenin in colorectal cancer are meager (19-21).

To characterize the molecule in charge of the role of post-translational modifier after the translation of β-catenin, Firestein et al (6) conducted high-throughput screening studies and found that only CDK8 resided in a region of copy number gain in nearly half of colon cancers. In addition, they confirmed by murine cell culture studies in the cases expressing CDK8, but not a kinase inactive version of CDK8, transformed immortal murine cells. Based on such a background, it was elucidated that CDK8 is an oncogene that
is amplified in colorectal cancer. Most CDKs play an important role in the regulation of cell cycle. CDK7, CDK8 and CDK9 regulate gene expression by the interaction with the transcriptional machinery. Particularly, together with its partners cyclin C, MED12 and MED13, CDK8 forms a large protein mediator complex ‘CDK8 module’ that plays a central role in the regulation of transcription. In addition, the components of the CDK8 module MED12 and MED13 act as the regulator of β-catenin activation (3, 22, 23). In addition, CDK8 could increase β-catenin by an indirect method, which is a method through E2F1 that suppresses β-catenin. Thus, CDK8 suppresses E2F1, and at the end, the ability of E2F1 suppressing β-catenin is reduced resulting in the increase of β-catenin (7). In addition, CDK8 is involved in the regulation of the cell cycle of normal cells by binding of the basal transcriptional machinery to transcription factors such as Notch (24) or p53 (25).

To confirm the relationship of CDK8 and β-catenin based on colorectal cancer tissues, immunohistochemical studies were performed. Based on CDK8 staining performed on the normal colon mucosa, tubular adenoma and adenocarcinoma, it was speculated that CDK8 is involved not only in the early stage of the formation of colorectal cancer but also in the progression and metastasis of adenocarcinoma. In addition, CDK8 was significantly associated with the expression pattern of β-catenin, it positively correlated to the expression of β-catenin in the nucleus or in the cytoplasm and inversely correlated to the staining of β-catenin on cell membrane, and thus the possibility whether WNT/β-catenin signal pathway could be controlled through CDK8 became of interest. It is thought that the activation of β-catenin through the regulation of CDK8 may widen the understanding of the development of colorectal cancer and also the understanding of the progression of colorectal cancer.

The experiments using colorectal cancer cell lines performed to assess the relationship of CDK8 and β-catenin comprehensively showed the results slightly lower than expectation, and thus it is considered that the regulation of the expression of β-catenin by CDK8 assessed through immunohistochemical staining may require slightly different interpretation. CDK8 inference was induced in the colon cancer cell lines expressing β-catenin strongly by the application of siRNA, and the alteration of the expression of β-catenin was examined. Noticeable reduction was observed in some cases; nonetheless, complete suppression was not shown, and in some cases, the expression of β-catenin was only slightly reduced, and thus it is considered to imply that in the expression of β-catenin, factors other than CDK8 are also involved. In addition, in the Western blot analysis performed in the absence of serum factors, CDK8 was reduced but the expression of β-catenin was rather elevated, which renders the hypothesis that the expression of β-catenin is influenced by CDK8 primarily doubtful. It is thought that such results are contradictory to the proposal of Firestein et al (6) that only CDK8 plays a role of post-translational modifier of β-catenin.

Firestein et al (6) produced the colon cancer cell line DLD1 that has the APC deletion and proliferate in the β-catenin-dependent manner, performed the supplement experiments using the colon cancer cell line HCT-117 with β-catenin-dependent proliferation, and reported the study results. The colon cancer cell lines used in our study were HCT-117, HT-29 and SNU-C5, and it is considered that the characteristics of these cells are different from DLD1. Based on their results, Firestein et al (6) reported that CDK8 plays an important role in the expression of β-catenin, and based on this, they strongly suggested the possibility of treatment of colon cancer through the regulation of CDK8. It is considered that it is reasonable to revise the theory as it is limited to a specific colon cancer.

In addition, it is thought that to accept directly the result of in vitro experiments as the theory of the development and progression of general tumors without additional validation procedures may be very limited. Nevertheless, based on our study performed on tumor tissues, it was confirmed that CDK8 and β-catenin play a very important role in the development, progression and metastasis process of colon cancer. In addition, it could be confirmed that the effective regulation of the expression of β-catenin through CDK8 is the proposal applicable only to some limited cases of colon cancer, and not applicable to all colon cancer. Therefore, it was understood that also the theory concerning the development of the treatment method for colon cancer through the regulation of CDK8 is applicable to certain very limited colon cancer.

Acknowledgements

This study was supported by National Research Foundation of Korea (NRF) Grant funded by the Ministry of Education, Science and Technology (MEST) through the Research Center for Resistant Cells (R13-2003-009).

References


